The structural perspective on CDK5

NeuroSignals

Volumn 12, Issue 4-5, 2003, Pages 164-172

  Mapelli, Marina ^a   Musacchio, Andrea ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Cyclin dependent kinase 2; Cyclin dependent kinase 5; Neuronal cyclin dependent kinase 5 activator; p25; p35; p39

Indexed keywords

AMINO ACID DERIVATIVE; CYCLIN A; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 6; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROLINE DERIVATIVE; PROTEIN; PROTEIN KINASE; PROTEIN P25; PROTEIN P35; PROTEIN P39; UNCLASSIFIED DRUG;

BRAIN DEVELOPMENT; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CATALYST; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REGULATION; ENZYME SPECIFICITY; HUMAN; NERVE DEGENERATION; NERVE GROWTH; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANIMALS; CDC2-CDC28 KINASES; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASES; ENZYME ACTIVATION; MODELS, MOLECULAR; NERVE TISSUE PROTEINS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0346749691     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074617     Document Type: Review

References (74)

1. Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C, Harlow E, Tsai LH: A family of human cdc2-related protein kinases. Embo J 1992;11:2909.
2. Huse M, Kuriyan J: The conformational plasticity of protein kinases. Cell 2002;109:275.
3. Johnson, LN, Noble ME, Owen DJ: Active and inactive protein kinases: Structural basis for regulation. Cell 1996:85:149.
4. Buzko O, Shokat KM: A kinase sequence database: Sequence alignments and family assignment. Bioinformatics 2002;18:1274.
5. Rubin GM, Yandell MD, Wortman JR, Gabor Miklos GL, Nelson CR, Hariharan IK, Fortini ME, Li PW, Apweiler R, Fleischmann W, Cherry JM, Henikoff S, Skupski MP, Misra S, Ashburner M, Birney E, Boguski MS, Brody T, Brokstein P, Celniker SE, Chervitz SA, Coates D, Cravchik A, Gabrielian A, Galle RF, Gelbart WM, George RA, Goldstein LS, Gong F, Guan P, Harris NL, Hay BA, Hoskins RA, Li J, Li Z, Hynes RO, Jones SJ, Kuehl PM, Lemaitre B, Littleton JT, Morrison DK, Mungall C, O'Farrell PH, Pickeral OK, Shue C, Vosshall LB, Zhang J, Zhao Q, Zheng XH, Zhong F, Zhong W, Gibbs R, Venter JC, Adams MD, Lewis S: Comparative genomics of the eukaryotes. Science 2000;287:2204.
6. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science 2002:298:1912.
7. Knighton DR, Zheng JH, Ten Eyck LF, Ashford VA, Xuong NH, Taylor SS, Sowadski JM: Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991;253:407.
8. Pavletich NP: Mechanisms of cyclin-dependent kinase regulation: Structures of CDKs, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 1999;287:821.
9. Adams JA: Activation loop phosphorylation and catalysis in protein kinases: Is there functional evidence for the autoinhibitor model? Biochemistry 2003;42:601.
10. Schulze-Gahmen U, De Bondt HL, Kim SH: High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: Bound waters and natural ligand as guides for inhibitor design. J Med Chem 1996:39:4540.
11. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH: Crystal structure of cyclin-dependent kinase 2. Nature 1993;363:595.
12. Liu J, Kipreos ET: Evolution of cyclin-dependent kinases (CDKs) and CDK-activating kinases (CAKs): Differential conservation of CAKs in yeast and metazoa. Mol Biol Evol 2000;17:1061.
13. Endicott JA, Noble ME, Tucker JA: Cyclin-dependent kinases: Inhibition and substrate recognition. Curr Opin Struct Biol 1999:9:738.
14. Morgan DO: Principles of CDK regulation. Nature 1995;374:131.
15. Obaya AJ, Sedivy JM: Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci 2002;59:126.
16. Xiong Y, Zhang H, Beach D: D type cyclins associate with multiple protein kinases and the NA replication and repair factor PCNA. Cell 1992;71:505.
17. Miyajima M, Nornes HO, Neuman T: Cyclin E is expressed in neurons and forms complexes with cdk5. Neuroreport 1995;6:1130.
18. Lew J, Huang QQ, Qi Z, Winkfein RJ, Aebersold R, Hunt T, Wang JH: A brain-specific activator of cyclin-dependent kinase 5. Nature 1994:371:423.
19. Tsai LH, Delalle I, Caviness VS Jr, Chae T, Harlow E: p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 1994;371:419.
20. Ishiguro K, Kobayashi S, Omori A, Takamatsu M, Yonekura S, Anzai K, Imahori K, Uchida T: Identification of the 23 kDa subunit of tau protein kinase II as a putative activator of cdk5 in bovine brain. FEBS Lett 1994;342:203.
21. Uchida T, Ishiguro K, Ohnuma J, Takamatsu M, Yonekura S, Imahori K: Precursor of cdk5 activator, the 23 kDa subunit of tau protein kinase II: Its sequence and developmental change in brain. FEBS Lett 1994;355:35.
22. Qi Z, Huang QQ, Lee KY, Lew J, Wang JH: Reconstitution of neuronal Cdc2-like kinase from bacteria-expressed Cdk5 and an active fragment of the brain-specific activator: Kinase activation in the absence of Cdk5 phosphorylation. J Biol Chem 1995;270:10847.
23. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP: Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995;376:313.
24. Brown NR, Noble ME, Lawrie AM, Morris MC, Tunnah P, Divita G, Johnson LN, Endicott JA: Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J Biol Chem 1999:274:8746.
25. Russo AA, Jeffrey PD, Pavletich NP: Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol 1996:3:696.
26. Brown NR, Noble ME, Endicott JA, Johnson LN: The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat Cell Biol 1999;1:438.
27. Lew J: MAP kinases and CDKs: Kinetic basis for catalytic activation. Biochemistry 2003;42:849.
28. Tarricone C, Dhavan R, Peng J, Areces LB, Tsai L, Musacchio A: Structure and regulation of the cdk5-p25(nck5a) complex. Mol Cell 2001;8:657.
29. Hagopian JC, Kirtley MP, Stevenson LM, Gergis RM, Russo AA, Pavletich NP, Parsons SM, Lew J: Kinetic basis for activation of CDK2/cyclin A by phosphorylation. J Biol Chem 2001;276:275.
30. Brown NR, Noble ME, Endicott JA, Garman EF, Wakatsuki S, Mitchell E, Rasmussen B, Hunt T, Johnson LN: The crystal structure of cyclin A. Structure 1995;3:1235.
31. Tang D, Chun ACS, Zhang M, Wang JH: Cyclin-dependent kinase 5 (Cdk5) activation domain of neuronal Cdk5 activator: Evidence of the existence of cyclin fold in neuronal Cdk5a activator. J Biol Chem 1997;272:12318.
32. Chou KC, Watenpaugh KD, Heinrikson RL: A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator. Biochem Biophys Res Commun 1999;259:420.
33. Gibson TJ, Thompson JD, Blocker A, Kouzarides T: Evidence for a protein domain superfamily shared by the cyclins, TFIIB and RB/p107. Nucleic Acids Res 1994;22:946.
34. Cheng K, Li Z, Fu W-Y, Wang JH, Fu AKY, Ip NY: Pctaire1 interacts with p35 and is a novel substrate for Cdk5/p35. J Biol Chem 2002;277:31988-31993.
35. Chin KT, Ohki SY, Tang D, Cheng HC, Wang JH, Zhang M: Identification and structure characterization of a Cdk inhibitory peptide derived from neuronal-specific Cdk5 activator. J Biol Chem 1999;274:7120.
36. Sharma P, Sharma M, Amin ND, Albers RW, Pant HC: Regulation of cyclin-dependent kinase 5 catalytic activity by phosphorylation. Proc Natl Acad Sci USA 1999;96:11156.
37. Poon RY, Lew J, Hunter T: Identification of functional domains in the neuronal Cdk5 activator protein. J Biol Chem 1997;272:5703.
38. Nishizawa M, Kanaya Y, Toh EA: Mouse cyclin-dependent kinase (Cdk) 5 is a functional homologue of a yeast Cdk, pho85 kinase. J Biol Chem 1999;274:33859.
39. Graeser R, Gannon J, Poon RYC, Dubois T, Aitken A, Hunt T: Regulation of the CDK-related protein kinase PCTAIRE-1 and its possible role in neurite outgrowth in Neuro-2A cells. J Cell Sci 2002;115:3479.
40. Huang D, Patrick G, Moffat J, Tsai LH, Andrews B: Mammalian Cdk5 is a functional homologue of the budding yeast Pho85 cyclin-dependent protein kinase. Proc Natl Acad Sci USA 1999;96:14445.
41. Toh EA, Nishizawa M: Structure and function of cyclin-dependent Pho85 kinase of Saccharomyces cerevisiae. J Gen Appl Microbiol 2001;47:107.
42. Zukerberg LR, Patrick GN, Nikolic M, Humbert S, Wu CL, Lanier LM, Gertler FB, Vidal M, Van Etten RA, Tsai LH: Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron 2000;26:633.
43. Sasaki Y, Cheng C, Uchida Y, Nakajima O, Ohshima T, Yagi T, Taniguchi M, Nakayama T, Kishida R, Kudo Y, Ohno S, Nakamura F, Goshima Y: Fyn and Cdk5 mediate semaphorin-3A signaling, which is involved in regulation of dendrite orientation in cerebral cortex. Neuron 2002;35:907.
44. Matsuura I, Wang JH: Demonstration of cyclin-dependent kinase inhibitory serine/threonine kinase in bovine thymus. J Biol Chem 1996;271:5443.
45. Lowe ED, Noble MEM, Skamnaki VT, Oikonomakos NG, Owen DJ, Johnson LN: The crystal structure of a phosphorylase kinase peptide substrate complex: Kinase substrate recognition. EMBO J 1997;16:6646.
46. 2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24). EMBO J 1993;12:849.
47. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, Barford D: Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 2002;9:940.
48. Zheng J, Knighton DR, ten Eyck LF, Karlsson R, Xuong N, Taylor SS, Sowadski JM: Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry 1993;32:2154.
49. Songyang Z, Blechner S, Hoagland N, Hoekstra MF, Piwnica-Worms H, Cantley LC: Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr Biol 1994;4:973.
50. Songyang Z, Lu KP, Kwon YT, Tsai LH, Filhol O, Cochet C, Brickey DA, Soderling TR, Bartleson C, Graves DJ, De Maggio AJ, Hoekstra MF, Blenis J, Hunter T, Cantley LC: A structural basis for substrate specificities of protein Ser/Thr kinases: Primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol Cell Biol 1996;16:6486.
51. Sharma P, Barchi JJ Jr, Huang X, Amin ND, Jaffe H, Pant HC: Site-specific phosphorylation of Lys-Ser-Pro repeat peptides from neurofilament H by cyclin-dependent kinase 5: Structural basis for substrate recognition. Biochemistry 1998;37:4759.
52. Holmes JK, Solomon MJ: A predictive scale for evaluating cyclin-dependent kinase substrates: A comparison of p34cdc2 and p33cdk2. J Biol Chem 1996;271:25240.
53. Kitagawa M, Higashi H, Jung HK, Suzuki-Takahashi I, Ikeda M, Tamai K, Kato J, Segawa K, Yoshida E, Nishimura S, Taya Y: The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 1996;15:7060.
54. Higashi H, Suzuki-Takahashi I, Taya Y, Segawa K, Nishimura S, Kitagawa M: Differences in substrate specificity between Cdk2-cyclin A and Cdk2-cyclin E in vitro. Biochem Biophys Res Commun 1995;216:520.
55. Shetty KT, Link WT, Pant HC: cdc2-like kinase from rat spinal cord specifically phosphorylates KSPXK motifs in neurofilament proteins: Isolation and characterization. Proc Natl Acad Sci USA 1993;90:6844.
56. Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ: Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 1997;90:859.
57. Sharma P, Steinbach PJ, Sharma M, Amin ND, Barchi JJ Jr, Pant HC: Identification of substrate binding site of cyclin-dependent kinase 5. J Biol Chem 1999;274:9600.
58. Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH: Crystal structure of glycogen synthase kinase 3 beta: Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001;105:721.
59. Cohen P, Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769.
60. Beaudette KN, Lew J, Wang JH: Substrate specificity characterization of a cdc2-like protein kinase purified from bovine brain. J Biol Chem 1993;268:20825.
61. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP: Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996;382:325.
62. Lee MH, Nikolic M, Baptista CA, Lai E, Tsai LH, Massague J: The brain-specific activator p35 allows Cdk5 to escape inhibition by p27Kip1 in neurons. Proc Natl Acad Sci USA 1996;93:3259.
63. Ching YP, Pang AS, Lam WH, Qi RZ, Wang JH: Identification of a neuronal Cdk5 activator-binding protein as Cdk5 inhibitor. J Biol Chem 2002;277:15237.
64. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH: Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999;402:615.
65. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH: Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000;405:360.
66. Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S: Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 2000;275:17166.
67. Nath R, Davis M, Probert AW, Kupina NC, Ren X, Schielke GP, Wang KK: Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem Biophys Res Commun 2000;274:16.
68. Patzke H, Tsai LH: Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29. J Biol Chem 2002:277:8054.
69. Dhavan R, Tsai LH: A decade of cdk5. Nat Rev Mol Cell Biol 2001;2:749.
70. Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J: Superti-Furga, G: A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 2003;112:845.
71. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J: Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003;112:859.
72. Knockaert M, Greengard P, Meijer L: Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002;23:417.
73. Capdeville R, Buchdunger E, Zimmermann J, Matter A: Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493.
74. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000;289:1938.